Biogen (BIIB) FCF Margin Growth (1y) (2010 - 2026)
Biogen (BIIB) FCF Margin Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 1,688.00 |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -1,334.00 |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 1,096.00 |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -647.00 |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -158.00 |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 1,388.00 |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 3,383.00 |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 1,020.00 |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 69.00 |
| 10 | Biogen | 32.04 Bn | 30.76 Bn | 1.96 Bn | 984.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 984.00 |
| Mar 31, 2026 | 1,484.00 |
| Dec 31, 2025 | -886.00 |
| Sep 30, 2025 | 1,186.00 |
| Jun 30, 2025 | -1,895.00 |
| Mar 31, 2025 | -1,301.00 |
| Dec 31, 2024 | 3,161.00 |
| Sep 30, 2024 | 1,604.00 |
| Jun 30, 2024 | 709.00 |
| Mar 31, 2024 | 637.00 |
| Dec 31, 2023 | 807.00 |
| Sep 30, 2023 | -351.00 |
| Jun 30, 2023 | -1,008.00 |
| Mar 31, 2023 | 1,168.00 |
| Dec 31, 2022 | -3,905.00 |
| Sep 30, 2022 | -347.00 |
| Jun 30, 2022 | -1,462.00 |
| Mar 31, 2022 | -2,100.00 |
| Dec 31, 2021 | 4,466.00 |
| Sep 30, 2021 | -503.00 |